Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

August 5, 2014

Primary Completion Date

June 12, 2017

Study Completion Date

September 15, 2017

Conditions
Solid Tumor
Interventions
DRUG

ASLAN001

ASLAN001 400mg BID daily; ASLAN001 500mg BID daily; or ASLAN001 300mg BID daily

DRUG

cisplatin + capecitabine

Cisplatin 80 mg/m2 IV infusion and capecitabine 1,000 mg/m2 orally BID for 14 days every 3 weeks

DRUG

cisplatin + 5-fluorouracil (or+ Leucovorin)

"Cisplatin 80 mg/m2 IV infusion and 5-fluorouracil 800 mg/m2/day IV infusion for 5 days every 3 weeks;~Or~Cisplatin 35 mg/m2 24-hour infusion for day 1 and day 8, 5-fluorouracil 2,000 mg/m2 and Leucovorin 300mg/m2 24-hour infusion for day 1, day 8 and day 15 every 4 weeks."

Trial Locations (3)

100

National Taiwan University Hospital, Taipei

112

Taipei Veterans General Hospital, Taipei

Unknown

Queen Mary Hospital, Hong Kong

Sponsors
All Listed Sponsors
lead

ASLAN Pharmaceuticals

OTHER

NCT02648425 - Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine | Biotech Hunter | Biotech Hunter